Accumulation of fluconazole in scalp hair

Journal of Clinical Pharmacology

Volumn 38, Issue 2, 1998, Pages 138-143

  Yeates, Rodney ^a   Laufen, Heinrich ^a   Zimmermann, Torsten ^a   Scharpf, Friedrich ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACCUMULATION; DRUG HALF LIFE; DRUG PENETRATION; FEMALE; HAIR ROOT; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; SCALP HAIR; TINEA CAPITIS;

EID: 0031908235     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04402.x     Document Type: Article

References (27)

1. Grant SM, Clissold SP: Fluconazole: a review of its pharmacodynamics and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990;39:877-916.
2. Chandrasekar PH, Gatny CM, and the Bone Marrow Transplantation Team: The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. J Antimicrob Agents Chemother 1994;33:309-318.
3. De Pauw BE, Raemaekers JMM, Donnelly JP, Kullberg B-J, Meis JFGM: An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Ann Hematol 1995;70:83-87.
4. Egger T, Gratwohl A, Tichelli A, Uhr M, Gysi CS, Passweg J, et al: Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients: a prospective, randomized, single-center study. Support Care Cancer 1995; 3:139-146.
5. Goa KL, Barradell LB: Fluconazole: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995;50:658-690.
6. Quagliarello VJ, Viscoli C, Horwitz RI: Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients. Lancet 1995;345:548-552.
7. Laine L, Rabeneck L: Prospective study of fluconazole suspension for the treatment of oesophageal candidiasis in patients with AIDS. Aliment Pharmacol Ther 1995;9:553-556.
8. Kotogyan A, Harmanyeri Y, Gunes AT, Erboz S, Palali Z, Sabuncu I, et al: Efficacy and safety of oral fluconazole in the treatment of patients with tinea corporis, cruris or pedis or cutaneous candidiasis: a multicentre, open, noncomparative study. Clin Drug Invest 1996;12:59-66.
9. Suchil P, Montera Gei F, Robles M, Perera-Ramirez A, Welsh O, Male O: Once-weekly oral doses of fluconazole 150 mg in the treatment of tinea corporis/cruris and cutaneous candidiasis. Clin Exp Dermatol 1992;17:397-401.
10. Fishbein A, Haneke E, Lacner K, Male O, Mohn R, Muller H, et al: Comparative evaluation of oral fluconazole and oral ketoconazole in the treatment of fungal infections of the skin. Int J Dermatol 1992;31(suppl 2):12-16.
11. Del Aguila R, Montero Gei F, Robles M, Perera-Ramirez A, Male O: Once-weekly oral doses of fluconazole 150 mg in the treatment of tinea pedis. Clin Exp Dermatol 1992;17:402-406.
12. Kookkanen K, Alava S: Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat 1992; 3:115-117.
13. Montero-Gei F, Robles-Soto ME, Schlager H: Fluconazole in the treatment of severe onychomycosis. Int J Dermatol 1996; 35:587-588.
14. Nahass GT, Sisto M: Onychomycosis: successful treatment with once-weekly fluconazole. Dermatology 1993;186:59-61.
15. Wildfeuer A, Faergemann J, Laufen H, Pfaff G, Zimmermann T, Seidl HP, et al: Bioavailability of fluconazole in the skin after oral medication. Mycoses 1994;37:127-130.
16. Faergemann J, Laufen H: Levels of fluconazole in serum stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat. Clin Exp Dermatol 1993;18:102-106.
17. Hay RJ: Pharmacokinetic evaluation of fluconazole in skin and nails. Int J Dermatol 1992;31(suppl 2):6-7.
18. Faergemann J, Laufen H: Levels of fluconazole in normal and diseased nails during and after treatment of onychomycoses in toe-nails with fluconazole 150 mg once weekly. Acta Dermatol Venereol (Stockholm) 1996;76:219-221.
19. Brammer KW, Farrow PR, Faulkner JK: Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990;12(suppl 3):S318-S326.
20. Solomon LM (ed.): Tinea Capitis: Current Concepts. Special Symposia in Pediatric Dermatology 1985;2:224-237.
21. Elewski BE, Hay RJ: International summit on cutaneous antifungal therapy, focus on tinea capitis, Boston, MA, November 11-13, 1994. Pediatr Dermatol 1996;13:69-77.
22. Frieden IJ, Howard R: Tinea capitis: epidemiology, diagnosis, treatment, and control. J Am Acad Dermatol 1994;31(suppl):S42-S46.
23. Abdel-Rahman SM, Nahata MC, Powell DA: Response to initial griseofulvin therapy in pediatric patients with tinea capitis. Ann Pharmacother 1997;31:406-410.
24. Gatti S, Marinaro C, Bianchi L, Nini G: Treatment of kerion with fluconazole (letter). Lancet 1991;338:1156.
25. Montero-Gei F, Melendez M: Fluconazole treatment of dermatophytosis in children (abstract). Presented at the Twelfth Congress of the International Society for Human and Animal Mycology, Adelaide, Australia, March, 1994. P9.2.
26. Wildfeuer A, Seidl HP: Comparison of the in vitro activity of fluconazole against Candida albicans and dermatophytes. Arzneim Forschr Drug Res 1995;7:819-821.
27. Solomon BA, Collins R, Sharma R, Silverberg N, Jain AR, Sedgh J, et al: Fluconazole for the treatment of tinea capitis in children. J Am Acad Dermatol 1997;37:274-275.